acute myeloid leukemia

[Oncogene] The authors used MLL-AF9-induced AML mouse models with interferon regulatory factor 7 (IRF7) knockout or overexpression and xenograft mouse models to explore the intrinsic effects of IRF7 in AML.

[Nature Medicine] Through integrative molecular profiling of HSCs and progenitor cells in large patient cohorts, scientists found that myelodysplastic syndromes HSCs in two distinct differentiation states were maintained throughout the clinical course of the disease.

[Leukemia] Researchers studied acute promyelocytic leukemia (APLs) with different leukemia-initiating cells (LICs) frequencies and investigated the effect of two HDAC inhibitors: valproic acid, with relative selectivity towards class I HDAC enzymes and vorinostat/suberoylanilide hydroxamic acid in combination with all-trans retinoic acid, on the bulk APL cells and APL LICs.

[Intellia Therapeutics, Inc.] Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML.

[Science Translational Medicine] Reduced-intensity conditioning for HLA-haploidentical hematopoietic cell transplantation was augmented with same-donor memory-like natural killer (NK) cells on day +7 and 3 weeks of N-803 to treat patients with relapsed/refractory AML in a clinical trial.

[Blood] As BCL2 was an important determinant of survival of both myeloid progenitor and B cells, researchers investigated whether clinical and molecular abnormalities arise in the myeloid compartment during long-term continuous venetoclax treatment of chronic lymphocytic leukemia in 89 patients.